Short summary

Prospective, observational biomarker and registration study. All patients treated with SBRT, SRS and SIB for metastases at Vejle Hospital will be offered inclusion in the study. Patients will be stratified according to three cohorts: • Cohort A: Stereotactic body radiotherapy (SBRT) for oligometastatic disease or oligometastatic progression • Cohort B: Brain stereotactic radiosurgery (SRS) for oligometastatic disease or oligometastatic progression • Cohort C: Radiotherapy with simultaneous integ

Rationale

The study aims to investigate toxicity, quality of life (QoL), circulating tumor-specific DNA (ctDNA), and efficacy of stereotactic body radiotherapy (SBRT), brain stereotactic radiosurgery (SRS), and conventional radiotherapy with simultaneous integrated boost (SIB) in the pelvis. Overall, the study will validate the treatment strategy in each patient group, the value of ctDNA, and create baseline and follow-up data for toxicity, QoL, local control and survival for reference, as techniques and indications evolve over time.

Description of the cohort

• Cohort A: Stereotactic body radiotherapy (SBRT) for oligometastatic disease or oligometastatic progression • Cohort B: Brain stereotactic radiosurgery (SRS) for oligometastatic disease or oligometastatic progression • Cohort C: Radiotherapy with simultaneous integ

Data and biological material

circulating tumor-specific DNA at baseline and after 3 months

Collaborating researchers and departments

Department of Oncology, Vejle Hospital

• Christine Vestergård Madsen, MD, PhD
• Thomas Leth Fink, MD

Department of Biochemistry and Immunology, Vejle Hospital

• Rikke Fredslund Andersen, MSc, PhD
• Søren Kahns, MSc, PhD